• ProMIS Neurosciences is trading at $11.50 (-5.74%) today.
  • Chardan initiated coverage on PMN with a "Buy" rating and a $20.00 price target, suggesting significant upside potential.
  • The stock's decline comes amidst recent positive developments, including promising clinical trial data for its Alzheimer's disease drug candidate, PMN310, and the full enrollment of its Phase 1b PRECISE-AD trial, presented at AAIC 2026.
  • Despite the positive analyst outlook, the stock continues to pull back from recent gains, indicating potential profit-taking in the short term.